BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang W, Xiong Y, Li X, Yang Y. Cardiac Fibrosis: Cellular Effectors, Molecular Pathways, and Exosomal Roles. Front Cardiovasc Med 2021;8:715258. [PMID: 34485413 DOI: 10.3389/fcvm.2021.715258] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Duangrat R, Parichatikanond W, Likitnukul S, Mangmool S. Endothelin-1 Induces Cell Proliferation and Myofibroblast Differentiation through the ET(A)R/G(αq)/ERK Signaling Pathway in Human Cardiac Fibroblasts. Int J Mol Sci 2023;24. [PMID: 36901906 DOI: 10.3390/ijms24054475] [Reference Citation Analysis]
2 Kraus L, Beavens B. The Current Therapeutic Role of Chromatin Remodeling for the Prognosis and Treatment of Heart Failure. Biomedicines 2023;11. [PMID: 36831115 DOI: 10.3390/biomedicines11020579] [Reference Citation Analysis]
3 Yuan J, Yang H, Liu C, Shao L, Zhang H, Lu K, Wang J, Wang Y, Yu Q, Zhang Y, Yu Y, Shen Z. Microneedle Patch Loaded with Exosomes Containing MicroRNA-29b Prevents Cardiac Fibrosis after Myocardial Infarction. Adv Healthc Mater 2023;:e2202959. [PMID: 36739582 DOI: 10.1002/adhm.202202959] [Reference Citation Analysis]
4 Scuruchi M, Mannino F, Imbesi C, Pallio G, Vermiglio G, Bagnato G, Minutoli L, Bitto A, Squadrito F, Irrera N. Biglycan Involvement in Heart Fibrosis: Modulation of Adenosine 2A Receptor Improves Damage in Immortalized Cardiac Fibroblasts. Int J Mol Sci 2023;24. [PMID: 36675295 DOI: 10.3390/ijms24021784] [Reference Citation Analysis]
5 Bertaud A, Joshkon A, Heim X, Bachelier R, Bardin N, Leroyer AS, Blot-Chabaud M. Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis. Int J Mol Sci 2023;24. [PMID: 36675283 DOI: 10.3390/ijms24021756] [Reference Citation Analysis]
6 Dieterlen MT, Klaeske K, Spampinato R, Marin-Cuartas M, Wiesner K, Morningstar J, Norris RA, Melnitchouk S, Levine RA, van Kampen A, Borger MA. Histopathological insights into mitral valve prolapse-induced fibrosis. Front Cardiovasc Med 2023;10:1057986. [PMID: 36960475 DOI: 10.3389/fcvm.2023.1057986] [Reference Citation Analysis]
7 Tian Y, Tsujisaka Y, Li VY, Tani K, Lucena-cacace A, Yoshida Y. Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids. Front Cell Dev Biol 2022;10. [DOI: 10.3389/fcell.2022.1001453] [Reference Citation Analysis]
8 Paek HJ, Quan BH, Choe HM, Li ZY, Yin XJ. Myostatin deficiency decreases cardiac extracellular matrix in pigs. Transgenic Res 2022. [PMID: 35978205 DOI: 10.1007/s11248-022-00322-w] [Reference Citation Analysis]
9 Fan J, Ren M, He Y. Diagnostic and Therapeutic Properties of Exosomes in Cardiac Fibrosis. Front Cell Dev Biol 2022;10:931082. [DOI: 10.3389/fcell.2022.931082] [Reference Citation Analysis]
10 Stojanovic D, Mitic V, Stojanovic M, Milenkovic J, Ignjatovic A, Milojkovic M. The Scientific Rationale for the Introduction of Renalase in the Concept of Cardiac Fibrosis. Front Cardiovasc Med 2022;9:845878. [PMID: 35711341 DOI: 10.3389/fcvm.2022.845878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Aimo A, Spitaleri G, Nieri D, Tavanti LM, Meschi C, Panichella G, Lupón J, Pistelli F, Carrozzi L, Bayes-genis A, Emdin M. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev 2022;8:e12. [DOI: 10.15420/cfr.2021.30] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, Wang Y, Fu C, Jiang Y, He C, Wei Q. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduct Target Ther 2022;7:78. [PMID: 35273164 DOI: 10.1038/s41392-022-00925-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 40.0] [Reference Citation Analysis]
13 Bourque K, Jones-tabah J, Hébert TE. Tools for drug discovery and disease modeling- the future is upon us. Methods 2022. [DOI: 10.1016/j.ymeth.2022.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]